KAZA1
MCID: KLZ004
MIFTS: 41

Kala-Azar 1 (KAZA1)

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Kala-Azar 1

MalaCards integrated aliases for Kala-Azar 1:

Name: Kala-Azar 1 56
Kala-Azar, Susceptibility to, 1 56 13
Leishmaniasis 58 71
Leishmaniasis, Visceral, Susceptibility to, 1 56
Leishmaniasis, Visceral 1 56
Kaza1 56

Characteristics:

Orphanet epidemiological data:

58
leishmaniasis
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-5/10000 (Worldwide); Age of onset: All ages;

Classifications:

Orphanet: 58  
Rare infectious diseases


External Ids:

OMIM 56 608207
OMIM Phenotypic Series 56 PS608207
MESH via Orphanet 44 D007896
ICD10 via Orphanet 33 B55.0 B55.1 B55.2 more
UMLS via Orphanet 72 C0023281
Orphanet 58 ORPHA507
UMLS 71 C0023281

Summaries for Kala-Azar 1

MalaCards based summary : Kala-Azar 1, also known as kala-azar, susceptibility to, 1, is related to cutaneous leishmaniasis and visceral leishmaniasis, and has symptoms including fever, pruritus and exanthema. An important gene associated with Kala-Azar 1 is KAZA1 (Kala-Azar (Visceral Leishmaniasis), Susceptibility To). The drugs Lidocaine and Amphotericin B have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and skin, and related phenotypes are splenomegaly and hepatomegaly

More information from OMIM: 608207 PS608207

Related Diseases for Kala-Azar 1

Diseases in the Kala-Azar 1 family:

Kala-Azar 2 Kala-Azar 3

Diseases related to Kala-Azar 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 596)
# Related Disease Score Top Affiliating Genes
1 cutaneous leishmaniasis 13.0
2 visceral leishmaniasis 13.0
3 mucocutaneous leishmaniasis 12.9
4 leishmaniasis, tegumentary 12.4
5 kala-azar 2 11.7
6 kala-azar 3 11.7
7 chronic rhinitis 11.6
8 leishmaniasis 11.4
9 splenomegaly 10.9
10 pancytopenia 10.8
11 chagas disease 10.8
12 hansen's disease 10.7
13 leprosy 3 10.7
14 immune deficiency disease 10.6
15 skin disease 10.6
16 acquired immunodeficiency syndrome 10.6
17 trypanosomiasis 10.6
18 cytokine deficiency 10.5
19 human immunodeficiency virus type 1 10.5
20 neutropenia 10.5
21 triiodothyronine receptor auxiliary protein 10.5
22 allergic hypersensitivity disease 10.5
23 malaria 10.5
24 sleeping sickness 10.4
25 schistosoma mansoni infection, susceptibility/ 10.4
26 schistosomiasis 10.4
27 hemophagocytic lymphohistiocytosis 10.4
28 thrombocytopenia 10.4
29 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.4
30 toxoplasmosis 10.4
31 diarrhea 10.4
32 bacterial infectious disease 10.4
33 lupus erythematosus 10.4
34 exanthem 10.4
35 autoimmune disease 10.3
36 erysipeloid 10.3
37 glomerulonephritis 10.3
38 systemic lupus erythematosus 10.3
39 sporotrichosis 10.3
40 lepromatous leprosy 10.3
41 filariasis 10.3
42 uveitis 10.3
43 pulmonary tuberculosis 10.3
44 47,xyy 10.3
45 acute kidney failure 10.3
46 kidney disease 10.3
47 vasculitis 10.3
48 dermatitis 10.3
49 alopecia 10.3
50 rheumatoid arthritis 10.2

Graphical network of the top 20 diseases related to Kala-Azar 1:



Diseases related to Kala-Azar 1

Symptoms & Phenotypes for Kala-Azar 1

Human phenotypes related to Kala-Azar 1:

58 (show all 25)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 splenomegaly 58 Very frequent (99-80%)
2 hepatomegaly 58 Very frequent (99-80%)
3 fatigue 58 Occasional (29-5%)
4 weight loss 58 Frequent (79-30%)
5 anemia 58 Frequent (79-30%)
6 arthralgia 58 Frequent (79-30%)
7 papule 58 Very frequent (99-80%)
8 skin ulcer 58 Very frequent (99-80%)
9 elevated hepatic transaminase 58 Frequent (79-30%)
10 pallor 58 Frequent (79-30%)
11 thrombocytopenia 58 Occasional (29-5%)
12 anorexia 58 Occasional (29-5%)
13 abnormal bleeding 58 Very frequent (99-80%)
14 hypoalbuminemia 58 Frequent (79-30%)
15 abnormal oral mucosa morphology 58 Very frequent (99-80%)
16 lymphadenopathy 58 Very frequent (99-80%)
17 increased antibody level in blood 58 Frequent (79-30%)
18 pancytopenia 58 Very frequent (99-80%)
19 leukopenia 58 Occasional (29-5%)
20 abnormal oral cavity morphology 58 Very frequent (99-80%)
21 recurrent fever 58 Very frequent (99-80%)
22 abnormal macrophage morphology 58 Very frequent (99-80%)
23 rhinitis 58 Very frequent (99-80%)
24 skin plaque 58 Very frequent (99-80%)
25 night sweats 58 Very frequent (99-80%)

Clinical features from OMIM:

608207

UMLS symptoms related to Kala-Azar 1:


fever, pruritus, exanthema

Drugs & Therapeutics for Kala-Azar 1

Drugs for Kala-Azar 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 110)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
2
Amphotericin B Approved, Investigational Phase 4 1397-89-3 5280965 14956
3
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
4
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
5
Dimethyl sulfoxide Approved, Vet_approved Phase 4 67-68-5 679
6
deoxycholic acid Approved Phase 4 83-44-3 222528
7
meglumine antimoniate Experimental, Investigational Phase 4 133-51-7
8 Anesthetics Phase 4
9 Anti-Infective Agents Phase 4
10 Antiprotozoal Agents Phase 4
11 Antiparasitic Agents Phase 4
12 Antifungal Agents Phase 4
13 Liposomal amphotericin B Phase 4
14 Antioxidants Phase 4
15 Protective Agents Phase 4
16 Amebicides Phase 4
17 Anti-Bacterial Agents Phase 4
18 Gastrointestinal Agents Phase 4
19 Amphotericin B, deoxycholate drug combination Phase 4
20
Pentoxifylline Approved, Investigational Phase 2, Phase 3 6493-05-6 4740
21
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
22
Pentamidine Approved, Investigational Phase 2, Phase 3 100-33-4 4735
23
carbamide peroxide Approved Phase 2, Phase 3 124-43-6
24
Aluminum sulfate Approved Phase 2, Phase 3 10043-01-3
25
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
26
Zinc Approved, Investigational Phase 2, Phase 3 7440-66-6 32051
27
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
28
Zinc sulfate Approved, Investigational Phase 2, Phase 3 7733-02-0
29
Paromomycin Approved, Investigational Phase 2, Phase 3 7542-37-2, 1263-89-4 165580
30
Miltefosine Approved, Investigational Phase 3 58066-85-6 3600
31
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
32
Azithromycin Approved Phase 2, Phase 3 83905-01-5 447043 55185
33
Nitric Oxide Approved Phase 3 10102-43-9 145068
34
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
35 Molgramostim Investigational Phase 3 99283-10-0
36
BCG vaccine Investigational Phase 2, Phase 3
37 Tocotrienol Investigational Phase 3 6829-55-6
38 Vaccines Phase 2, Phase 3
39 Phosphodiesterase Inhibitors Phase 2, Phase 3
40 Platelet Aggregation Inhibitors Phase 2, Phase 3
41 Radiation-Protective Agents Phase 2, Phase 3
42 Adjuvants, Immunologic Phase 3
43 interferons Phase 3
44 Immunologic Factors Phase 3
45 Vitamins Phase 3
46 Tocotrienols Phase 3
47 Tocopherols Phase 3
48 Dermatologic Agents Phase 2, Phase 3
49 Anthelmintics Phase 3
50 Antimony Sodium Gluconate Phase 3

Interventional clinical trials:

(show top 50) (show all 171)
# Name Status NCT ID Phase Drugs
1 Point of Care Diagnosis and Treatment With Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India. Unknown status NCT01566552 Phase 4 AMBISOME
2 Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients Infected With Leishmania (Viannia) Braziliensis in Bahia State, Brazil. An Open Uncontrolled Trial. Completed NCT00818818 Phase 4 Meglumine antimoniate
3 Efficacy and Safety of Amphotericin B Deoxycholate Compared to Meglumine Antimoniate for Treatment of Visceral Leishmaniasis in Brazilian Children Completed NCT01032187 Phase 4 Meglumine antimoniate;Amphotericin B-deoxycholate
4 Pharmacokinetics of Miltefosine in Children and Adults: Implications for the Treatment of Cutaneous Leishmaniasis in Colombia. Completed NCT01462500 Phase 4 Miltefosine
5 Safety and Effectiveness of Short-course AmBisome in the Treatment of Post-Kala-azar Dermal Leishmaniasis (PKDL): a Prospective Cohort Study in Bangladesh Completed NCT03311607 Phase 4 AmBisome
6 Phase IV Randomized Controlled Clinical Trial to Evaluate the Safety and Efficacy of Low-Dose Pentavalent Antimony Compared to the Standard Dose in Patients With Cutaneous Leishmaniasis Caused by Leishmania (Viannia)Braziliensis Completed NCT00317980 Phase 4 Meglumine antimoniate;Meglumine antimoniate
7 A Phase 4 Study to Expand Access Program While Assessing the Safety and Efficacy of Paromomycin IM Injection in an Outpatient Setting for the Treatment of Visceral Leishmaniasis Completed NCT00604955 Phase 4 Paromomycin sulfate
8 A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL) Completed NCT01975051 Phase 4 Mitefosine
9 An Open Label Study of RFH Therapy as Treatment for CL Caused by Leishmania Tropica in India Completed NCT01661296 Phase 4 Sodium stibogluconate
10 Comparison of Effectiveness of Topical Amphotericin B in 30% Dimethylsulphoxide and 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis: Randomized Double Blind Controlled Trial Pilot Study Recruiting NCT03814343 Phase 4 amphotericin B in 30% DMSO;30% DMSO
11 Multicentric Efficacy and Safety Study of Antileishmanial Drugs for Treatment of Visceral Leishmaniasis in Brazil Terminated NCT01310738 Phase 4 Antimoniate of N-methylglucamine;amphotericin B deoxycholate;Liposomal amphotericin B;Liposomal amphotericin B;Antimoniate of N-methylglucamine
12 Randomized Clinical Trial of the Efficacy and Tolerability of Oral Miltefosine Versus Parenteral Antimony for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia Unknown status NCT00487253 Phase 3 Miltefosine;Meglumine antimoniate
13 Randomized, Open-label, Parallel-group, Safety & Efficacy Study to Evaluate Different Combination Treatment Regimens, of Either AmBisome and Paromomycin, AmBisome and Miltefosine, or Paromomycin and Miltefosine Compared With Amphotericin B Deoxycholate (the Standard) Therapy for the Treatment of Acute, Symptomatic Visceral Leishmaniasis (VL). Completed NCT00696969 Phase 3 Amphotericin B Deoxycholate;Ambisome + Miltefosine;Ambisome and Paromomycin;Miltefosine and Paromomycin
14 A Phase 3 Multicenter, Randomized, Controlled, Clinical Trial to Assess the Safety and Efficacy of Injectable Paromomycin in Patients With Visceral Leishmaniasis Completed NCT00216346 Phase 3 Paromomycin sulfate;Amphotericin B
15 Double-blind Placebo Controlled Trial Using Pentoxifylline Associated With Pentavalent Antimony in Cutaneous Leishmaniasis Completed NCT01381055 Phase 2, Phase 3 Pentoxifylline;Placebo
16 Randomized Double Blind Clinical Trial of Imiquimod (Aldara) Versus Placebo Used in Combination With Pentavalent Antimony (Glucantime) in Peruvian Cutaneous Leishmaniasis Patients Completed NCT00257530 Phase 3 Imiquimod
17 A Prospective, Multicentric, Randomized, Two Arm, Open Label Phase III Study To Assess Efficacy And Safety Of Infusion Of Amphomul® (Amphotericin B Emulsion) As Compared To Liposomal Amphotericin In Patients Of Visceral Leishmaniasis (Kala Azar) Completed NCT00876824 Phase 3 Amphotericin B Lipid emulsion;Liposomal Amphotericin B
18 Topical Paromomycin Cream For Bolivian Cutaneous Eishmaniasis: A Controlled Study Completed NCT03096457 Phase 2, Phase 3 Paromomycin Sulfate;Pentamidine Isethionate
19 Evaluation of Efficacy of Intra-lesional Injections of Glucantime Once Weekly in Comparison With Twice Weekly in the Treatment of Acute Anthroponotic Cutaneous Leishmaniasis (ACL) Completed NCT04340128 Phase 3 Meglumine antimoniate;Meglumine antimoniate
20 Phase 2 Study Electrothermocauterisation of Afghan Patients With Anthroponotic Cutaneous Leishmaniasis With and Without Pharmaceutical Chlorite Listed in the German Drug Codex (DAC N-055) Completed NCT00947362 Phase 2, Phase 3 DAC N-055;saline
21 A Phase III Randomized, Controlled, Clinical Trial to Assess the Safety and Efficacy of Single Infusion of Liposomal Amphotericin B in Patients With Visceral Leishmaniasis Completed NCT00628719 Phase 3 Liposomal Amphotericin B;amphotericin B deoxycholate
22 Efficacy Study of Liposomal Amphotericin in Disseminated Leishmaniasis Completed NCT02025491 Phase 3 Liposomal Amphotericin B
23 A Pivotal, Randomized, Double-blind, Vehicle-controlled Study to Evaluate WR 279,396 and Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia) Completed NCT00606580 Phase 3 WR 279,396 topical cream;Paromomycin Alone topical cream;Vehicle placebo cream
24 Therapeutic Gain of Adding the Immunomodulator Pentoxifylline to the Treatment of Cutaneous Leishmaniasis Completed NCT01464242 Phase 2, Phase 3 Meglumine antimonate;Placebo;Pentoxifylline
25 A Multicentre Comparative Trial of Efficacy and Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) Versus Combination of SSG and PM as the First Line Treatment for Visceral Leishmaniasis in Ethiopia, Kenya and Sudan Completed NCT00255567 Phase 3 Sodium Stibogluconate;Paromomycin sulphate;SSG and Paromomycin sulphate
26 Miltefosine and GM-CSF in Cutaneous Leishmaniasis: a Randomized and Controlled Trial Completed NCT03023111 Phase 3 Sbv;Miltefosine plus placebo;Miltefosine plus GM-CSF
27 A Randomized, Double-blind, Pivotal Phase 3 Study of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Alone Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama Completed NCT01790659 Phase 3 WR 279,396;Paromomycin
28 An Open Lable Randomised Two -Arm Study to Assess the Safety and Efficacy of Paromomycin Administered Intramuscularly at Two Different Dosing Regimens (14 Days Versus 21 Days) for the Treatment of Indian Visceral Leishmaniasis (VL) Completed NCT00629031 Phase 3 Paromomycin;Paromomycin
29 A Randomized, Safety, Immunogenicity & Efficacy Study of Autoclaved Leishmania Major Plus BCG vs. BCG (Double Blind) or Placebo (Open), in Healthy High Risk Iranian Volunteers With Positive Response to Leishmanin (LST>0) Completed NCT00429780 Phase 2, Phase 3
30 A Phase III, Open Label, Randomised, Study of Three Short Course Combination Regimens (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome® Alone for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh Completed NCT01122771 Phase 3 Liposomal amphotericin B;liposomal amphotericin B + miltefosine;liposomal amphotericin B + paromomycin;Miltefosine + Paromomycin
31 Phase 3, Clinical Trials of Drug Against Cutaneous Leishmaniasis Completed NCT00351520 Phase 3 Miltefose
32 A Randomised, Open-label, Parallel-group, Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens (Co-administration), of AmBisome, Paromomycin and Miltefosine in Visceral Leishmaniasis (VL) Completed NCT00523965 Phase 3 amphotericin B deoxycholate;Liposomal Amphotericin B with Miltefosine;Liposomal Amphotericin B and Paromomycin Sulfate;miltefosine + Paromomycin sulfate
33 A Randomized Trial of Ambisome Monotherapy and Combination of Ambisome and Miltefosine for the Treatment of VL in HIV Positive Patients in Ethiopia Followed by Secondary VL Prophylactic Treatment With Pentamidine. Completed NCT02011958 Phase 3 Liposomal Amphotericin B;Miltefosine
34 Phase III Clinical Trial for American Tegumentary Leishmaniasis: Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis Completed NCT01301924 Phase 2, Phase 3 Meglumine antimoniate
35 A Study for Safety and Efficacy of Miltefosine for Treatment of Children and Adolescents With Post-Kala-azar Dermal Leishmaniasis (PKDL) in Bangladesh and Association of Serum Vitamin E and Exposure to Arsenic With PKDL Completed NCT02193022 Phase 3 Miltefosine
36 Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia. Completed NCT00471705 Phase 3 Miltefosine;Glucantime®
37 A Randomized, Safety, Immunogenicity & Efficacy Study of Autoclaved Leishmania Major Plus BCG vs. BCG (Double Blind) or Placebo (Open), in Healthy High Risk Iranian Volunteers With no Response to Leishmanin Completed NCT00429715 Phase 2, Phase 3
38 Secondary Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients Using Pentamidine as a Prophylactic Agent: a Prospective Cohort Study Completed NCT01360762 Phase 3 Pentamidine
39 Replacement of Insecticides to Control Visceral Leishmaniasis Completed NCT01644682 Phase 3
40 A Randomized, Double Blind, Controlled Study to Determine the Efficacy of Zinc Supplementation on Diarrhea Incidence in an Adult Population in Western Kenya. Completed NCT01166815 Phase 2, Phase 3
41 Double Blind, Randomized, Placebo Controlled Clinical Trial for the Treatment of Diabetic Foot Ulcers, Using a Nitric Oxide Releasing Patch: PATHON Completed NCT00428727 Phase 3 Controlled nitric oxide releasing patch;placebo patch
42 Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis Recruiting NCT03829917 Phase 2, Phase 3 Miltefosine and Paromomycin;miltefosine;paromomycin
43 An Open Label, Phase III, Randomized Controlled, Multicentre Non-Inferiority Trial to Compare Efficacy and Safety of Miltefosine and Paromomycin With SSG and PM Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa Recruiting NCT03129646 Phase 3 Miltefosine;Paromomycin;Sodium stibogluconate
44 Phase III Clinical Trial for Mucosal or Mucocutaneous Leishmaniasis. Comparison Between the Standard and Alternative Antimonial Schemes Recruiting NCT01301937 Phase 2, Phase 3 Meglumine antimoniate
45 Randomised, Open Label, Multicentre, Non-inferiority Clinical Trial for New Treatment Modalities for Cutaneous Leishmaniasis Caused by Leishmania Tropica, in Pakistan Not yet recruiting NCT04268524 Phase 3
46 Phase 3 Randomized Trial Comparing Fluconazole to Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis Caused by L. Braziliensis and L. Guyanensis Terminated NCT01953744 Phase 3 Fluconazole;Meglumine Antimoniate
47 Open Label Randomized Study to Assess Safety and Efficacy of Azithromycin Versus Meglumine Antimoniate to Treat Cutaneous Leishmaniasis Terminated NCT00682656 Phase 2, Phase 3 Glucantime®;Zithromax ®
48 Effectiveness, Safety and Feasibility of Thermotherapy With the Hand-held Exothermic Crystallization Thermotherapy for Cutaneous Leishmaniasis (HECT-CL), Device for Cutaneous Leishmaniasis in Quetta, Pakistan Terminated NCT03208543 Phase 3
49 Double Blind, Randomized Controlled Trial, to Evaluate the Effectiveness of a Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis Terminated NCT00317629 Phase 3 controlled nitric oxide releasing patch;meglumine antimoniate
50 Phase 2 Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis Unknown status NCT00840359 Phase 2

Search NIH Clinical Center for Kala-Azar 1

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Antileishmanial [EPC]
Itraconazole
Ketoconazole
miltefosine

Genetic Tests for Kala-Azar 1

Anatomical Context for Kala-Azar 1

MalaCards organs/tissues related to Kala-Azar 1:

40
Testes, T Cells, Skin, Bone, Liver, Bone Marrow, Monocytes

Publications for Kala-Azar 1

Articles related to Kala-Azar 1:

(show top 50) (show all 21433)
# Title Authors PMID Year
1
Common variants in the HLA-DRB1-HLA-DQA1 HLA class II region are associated with susceptibility to visceral leishmaniasis. 56 61
23291585 2013
2
Genetic admixture in Brazilians exposed to infection with Leishmania chagasi. 61 56
19397557 2009
3
SLC11A1 (formerly NRAMP1) and susceptibility to visceral leishmaniasis in The Sudan. 56 61
14523377 2004
4
A major susceptibility locus on chromosome 22q12 plays a critical role in the control of kala-azar. 61 56
14557985 2003
5
Genetic control of visceral leishmaniasis in a Sudanese population: candidate gene testing indicates a linkage to the NRAMP1 region. 56 61
12618857 2003
6
The interplay between environmental and host factors during an outbreak of visceral leishmaniasis in eastern Sudan. 61 56
12475635 2002
7
Cytokine Gene Expression Alterations in Human Macrophages Infected by Leishmania major. 61
32347041 2021
8
Unbalanced production of LTB4/PGE2 driven by diabetes increases susceptibility to cutaneous leishmaniasis. 61
32525457 2020
9
Discovery of small molecule inhibitors of Leishmania braziliensis Hsp90 chaperone. 61
32048531 2020
10
An impedimetric genosensor for Leishmania infantum based on electrodeposited cadmium sulfide nanosheets. 61
32498918 2020
11
2-Amino-1,3,4-thiadiazoles as prospective agents in trypanosomiasis and other parasitoses. 61
32074064 2020
12
In vitro leishmanicidal activity of monoterpenes present in two species of Protium (Burseraceae) on Leishmania amazonensis. 61
32442591 2020
13
Vaccinomics strategy to concoct a promising subunit vaccine for visceral leishmaniasis targeting sandfly and leishmania antigens. 61
32311400 2020
14
New record of preclinical diagnosis of American visceral leishmaniasis in Amazonian Brazil encourages optimizing disease control. 61
32435706 2020
15
Nanoparticles: New agents toward treatment of leishmaniasis. 61
32566773 2020
16
Cutaneous Leishmaniasis Presenting as Macrocheilitis in a Postliver Transplant Pediatric Patient. 61
31688701 2020
17
Microscopic and molecular evidence in support of rodent as a reservoir for dissemination of Leishmaniasis. 61
32144860 2020
18
Unsuccessful treatment of cutaneous leishmaniasis by Leishmania infantum with topical paromomycin. 61
31975375 2020
19
The EP3622 clone of CD1a in the diagnosis of cutaneous leishmaniasis. 61
32144788 2020
20
Carvacrol loaded nanostructured lipid carriers as a promising parenteral formulation for leishmaniasis treatment. 61
32272211 2020
21
Oral delivery and enhanced efficacy of antimonal drug through macrophage-guided multifunctional nanocargoes against visceral Leishmaniasis. 61
32485227 2020
22
Comparative PCR-based diagnosis for the detection of Leishmania infantum in naturally infected dogs. 61
32305295 2020
23
Microautophagy upregulation in cutaneous lymph nodes of dogs naturally infected by Leishmania infantum. 61
32447515 2020
24
Antileishmanial activity evaluation of thiazolidine-2,4-dione against Leishmania infantum and Leishmania braziliensis. 61
32462293 2020
25
Molecular taxonomy and phylogenetic inferences of Bichromomyia flaviscutellata complex based on the COI gene DNA barcode region. 61
32084625 2020
26
The role of monocytes/macrophages in Leishmania infection: A glance at the human response. 61
32222362 2020
27
An overview of biochemically characterized drug targets in metabolic pathways of Leishmania parasite. 61
32504119 2020
28
Arginase and its mechanisms in Leishmania persistence. 61
32294247 2020
29
Cutaneous Leishmaniasis in Syrian Refugee Children: a Case Series. 61
32251258 2020
30
Binding of Leishmania spp with gold nanoparticles supported polyethylene glycol and its application for the sensitive detection of infectious photogenes in human plasma samples: A novel biosensor. 61
32266744 2020
31
Role of the translocase of the mitochondrial inner membrane in the import of tRNAs into mitochondria in Trypanosoma brucei. 61
32339625 2020
32
Human genetics of leishmania infections. 61
32055998 2020
33
Essential oil from leaves of Conobea scoparioides (Cham. & Schltdl.) Benth. (Plantaginaceae) causes cell death in HepG2 cells and inhibits tumor development in a xenograft model. 61
32574969 2020
34
When, Who, and How to Sample: Designing Practical Surveillance for 7 Neglected Tropical Diseases as We Approach Elimination. 61
32529261 2020
35
CCR5 and CCR5Δ32 in bacterial and parasitic infections: Thinking chemokine receptors outside the HIV box. 61
32212259 2020
36
TLR7 Sensing by Neutrophils Is Critical for the Control of Cutaneous Leishmaniasis. 61
32521271 2020
37
Spatial-Temporal Analysis of Lutzomyia trapidoi and Lutzomyia reburra (Diptera: Phlebotominae), in Rural Tourist Locations, Biosphere Reserve and Leishmaniasis Endemic Area, Ecuador. 61
32533171 2020
38
Highly sensitive UPLC-MS/MS method for the quantification of paromomycin in human plasma. 61
32199328 2020
39
Reconciling protective and pathogenic roles of the NLRP3 inflammasome in leishmaniasis. 61
32564424 2020
40
Cutaneous Leishmaniasis: A Case Study in the Context of Treatment with Adalimumab. 61
32571735 2020
41
Curative efficacy of purified serine protease inhibitor PTF3 from potato tuber in experimental visceral leishmaniasis. 61
32504996 2020
42
Predictors of relapse of visceral leishmaniasis in inner São Paulo State, Brazil. 61
32088340 2020
43
Leishmaniasis immunopathology-impact on design and use of vaccines, diagnostics and drugs. 61
32152715 2020
44
Conversion of asymptomatic infection to symptomatic visceral leishmaniasis: A study of possible immunological markers. 61
32555598 2020
45
Impact of Changes in Detection Effort on Control of Visceral Leishmaniasis in the Indian Subcontinent. 61
31841593 2020
46
Cutaneous Leishmaniasis due to Three Leishmania Species Among Syrian Refugees in Sanliurfa, Southeastern Turkey. 61
32557082 2020
47
Not-knowing and the proliferation of assumptions: local explanations of Cutaneous Leishmaniasis in Suriname. 61
31373516 2020
48
Genotyping the causative agents of cutaneous leishmaniasis in Ahvaz southwest of Iran. 61
32508419 2020
49
Designing of precise vaccine construct against visceral leishmaniasis through predicted epitope ensemble: A contemporary approach. 61
32339913 2020
50
Prevalence of Cutaneous Leishmaniasis in Iran (2000-2016): A Systematic Review and Meta-analysis Study. 61
32479248 2020

Variations for Kala-Azar 1

Expression for Kala-Azar 1

Search GEO for disease gene expression data for Kala-Azar 1.

Pathways for Kala-Azar 1

GO Terms for Kala-Azar 1

Sources for Kala-Azar 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....